Drug Database
TR

trivalent influenza vaccine (Istivac / Mutagrip S / Mutagrip)

✓ Approved

Sanofi S.A · 疫苗 · 疫苗

什么是 trivalent influenza vaccine?

trivalent influenza vaccine 是一种疫苗,由Sanofi S.A研发。该药已获批,用于治疗相关适应症,给药途径:Intradermal Injection、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

商品名Istivac, Mutagrip S, Mutagrip
公司Sanofi S.A
药物类别疫苗, 大分子
给药途径Intradermal Injection, Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved

相关研究文献

PubMedInfluenza and other respiratory viruses2026-11-17

A Canadian Laboratory-Based Retrospective of the 2024/2025 Influenza Season: Monitoring the Impacts of Influenza Evolution on Viral Antigenicity and Antiviral Susceptibility.

Ranadheera Charlene C, Gao Ruimin R, Buchanan Cody C, Frost Jasmine J et al.

Seasonal influenza affects thousands of Canadians each year and places significant strain on workplaces and the health systems. Robust laboratory-based surveillance is essential to monitor viral evolution and evaluate the suitability of medical countermeasures. The Canadian Influenza Surveillance Program characterizes circulating influenza viruses to determine genetic clades, monitor evolutionary trends, assess antigenicity and vaccine strain relatedness, and evaluate susceptibility to neuraminidase inhibitors. Methods include whole genome sequencing, hemagglutination inhibition assays, and neuraminidase inhibition assays. From September 1, 2024 to August 31, 2025, the program antigenically characterized 1563 influenza isolates identified and submitted by Canadian laboratories. Of these, 99.4% of influenza A/H1N1, 86.6% of influenza A/H3N2, and 100% of influenza B isolates were antigenically related to their respective component of the 2024-2025 Northern Hemisphere vaccine. Genetic analysis of influenza A/H3N2 isolates identified three distinct mutation clustering patterns associated with reduced antigenic reactivity to the vaccine strain. Additionally, 1567 influenza viruses underwent antiviral susceptibility testing. Eleven influenza A/H1N1 isolates showed reduced inhibition to oseltamivir and two to zanamivir, all containing known resistance-associated markers. These findings highlight the importance of comprehensive virological assessment, integrating genotypic and phenotypic data, to inform annual vaccine strain selection and support clinical decision-making.

PMID 43039871
阅读全文 →
PubMedFrontiers in veterinary science2026-11-17

Ginsenoside Rg1 as an adjuvant enhances immunity in chickens immunized with the H9N2 avian influenza inactivated vaccine.

Zhang Pengju P, Wang Hongtao H, Li Mengman M, Lyu Xuefeng X et al.

To investigate the potential use of Ginsenoside Rg1 as an adjuvant for the H9N2 avian influenza vaccine, the study examined Rg1's immunomodulatory effects on an inactivated H9N2 vaccine. A total of 150 one-day-old non-immunized Arbor Acres (AA) chickens were randomly assigned to three groups (n = 50 each): one receiving the H9N2 inactivated vaccine, another receiving Rg1 alongside the vaccine, and a control group treated with PBS. Each group underwent three immunization sessions spaced 2 weeks apart. Serum samples were taken to measure IgG antibody levels and hemagglutination inhibition (HI) titers. Lymphocyte proliferation was assessed using cell counting kits-8 and flow cytometry. The levels of serum cytokines, including Interferon-γ (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-4, and IL-6, were quantified via ELISA. Fourteen days post-final immunization, the chickens were challenged with the H9N2 strain, and viral titers in the lungs and kidneys were measured. Findings indicated that the group receiving Rg1 with the vaccine exhibited a notable increase in specific IgG and HI titers. Furthermore, this group showed enhanced T cell proliferation and elevated cytokine production, thereby bolstering cellular immunity. Importantly, the immune protection results revealed that the combination of Rg1 and the vaccine significantly improved the chickens' protection against viral strains, leading to a marked reduction in viral shedding. These findings imply that Rg1 may enhance the immune response and protective efficacy of the H9N2 inactivated vaccine, positioning it as a promising new adjuvant for H9N2 vaccination.

PMID 43041234
阅读全文 →
PubMedFrontiers in immunology2026-11-17

Effects of a multistrain probiotic formulation on immune response and microbiome modulation following influenza vaccination in adults: a randomised, triple-blind, placebo-controlled trial.

Naghibi Malwina M, Climent Sanz Eric E, Rodenes-Gavidia Andrea A, Illescas-Armijo Vanessa V et al.

Seasonal influenza remains a major global health burden, despite widespread vaccination. Vaccine responsiveness varies considerably between individuals and is increasingly recognised to be influenced by host factors, including the gut microbiome. Probiotics have been proposed as a strategy to modulate microbiome-immune interactions, although their effects on vaccine responses and the underlying microbial mechanisms remain incompletely understood. To investigate the effects of a probiotic formulation on immune responses and gut microbiome dynamics following seasonal influenza vaccination in healthy adults. In this randomised, triple-blind, placebo-controlled, multicentre trial, 120 healthy adults received either a 14-strain probiotic formulation (14 bacterial strains; 8 × 109 CFU/day, 40 mg vitamin C, and 2.5 μg vitamin B12) or placebo for six weeks, commencing three weeks before influenza vaccination and continuing for three weeks afterwards. The primary endpoint was change in strain-specific haemagglutination inhibition (HAI) antibody titres. Secondary endpoints included seroprotection and seroconversion rates, microneutralization activity, serum immune biomarkers and shotgun metagenomic analysis of the gut microbiome. Vaccination induced the expected increases in HAI antibody titres in both groups, with no significant differences between the active and placebo groups. The probiotic formulation was, however, associated with selective changes in the gut microbiome, including enrichment of the butyrate-producing species Roseburia inulinivorans and alterations in predicted microbial metabolic pathways, without affecting overall microbiome diversity. Participants who achieved seroprotection exhibited distinct compositional and functional microbiome responses to vaccination. These patterns included community-level changes that occurred predominantly in the active group, alongside taxonomic and functional differences associated with seroprotection. Although supplementation with the probiotic formulation did not increase influenza antibody responses, it did alter the gut microbiome response to vaccination, with selective changes in microbial composition and predicted functional potential while maintaining overall community diversity. Importantly, seroprotection was associated with distinct compositional and functional microbiome adaptations, and community-level changes associated with seroprotection occurred predominantly in the active group. Collectively, these findings support a microbiome-conditioning model in which the probiotic formulation shapes the gut microbiome response during vaccination, rather than acting as a direct immunostimulant. Future studies are required to determine whether these microbiome adaptations contribute causally to vaccine responsiveness. https://clinicaltrials.gov/study/NCT06103994, identifier NCT06103994.

PMID 43041926
阅读全文 →
PubMedGeriatrie et psychologie neuropsychiatrie du vieillissement2026-11-17

[2026 vaccination schedule for adults aged 65 years and older: towards comprehensive vaccine-based prevention in older age].

Corroyer-Simovic Bénédicte B

The 2026 French vaccination schedule redefines geriatric prevention, extending its focus beyond the prevention of infectious diseases to the preservation of independence and functional health. Yet vaccination coverage in France remains inadequate. To address immunosenescence, the strategy prioritizes comprehensive protection against respiratory infections caused by influenza viruses, SARS-CoV-2, pneumococcus and respiratory syncytial virus (RSV). For influenza, guidelines recommend the preferential use of enhanced vaccines-either high-dose or adjuvanted formulations-to improve protection in older adults and reduce hospital admissions. Covid-19 boosters remain essential for this vulnerable population, with the adjuvanted recombinant protein vaccine Nuvaxovid® available alongside mRNA vaccines. Pneumococcal prevention is considerably simplified: a single dose of the 21-valent pneumococcal conjugate vaccine (PCV21, Capvaxive®) is recommended for all adults aged 65 years and older. This vaccine covers the serotypes responsible for 83.5% of invasive pneumococcal disease cases in France in 2024. RSV vaccination is indicated for adults aged 75 years and older and for those aged 65 years and older with cardiopulmonary comorbidities, providing protection against severe disease and reducing hospital admissions during winter. Beyond respiratory infections, vaccination against herpes zoster with the adjuvanted recombinant vaccine Shingrix® is recommended for all adults aged 65 years and older. Recent data associate this vaccination not only with the prevention of postherpetic neuralgia but also with a reduced risk of stroke. Tdap-IPV boosters remain essential in the context of recent pertussis epidemics and the persistent risk of tetanus in older adults. Vaccine coadministration is safe and should be offered to improve coverage and reduce the number of visits required. When vaccination records are unavailable, the priority is to proceed with vaccination rather than delay protection. This proactive, integrated approach aims to address inadequate vaccination coverage, reduce mortality and preserve independence in older adults.

PMID 43042679
阅读全文 →
PubMedThe Journal of infectious diseases2026-11-17

A prospective, comparative cohort analysis of influenza antibody waning in Michigan and Hong Kong during periods of low influenza circulation.

Yang Yanyupei Y, Smith Matthew M, Ho Faith F, Truscon Rachel R et al.

Reduced influenza transmission during the COVID-19 pandemic prompted concern about waning of population immunity that could lead to subsequent surges in circulation. We compared longitudinal influenza antibody titers in Michigan and Hong Kong, two regions with reduced influenza transmission during the COVID-19 pandemic. In two prospective cohort studies (HIVE, Michigan; EPI-HK, Hong Kong), we analyzed longitudinal serum samples collected from 2020 through 2023 from participants without influenza infection or vaccination. Sera were tested using hemagglutination inhibition assays (HAI) and microneutralization (MN) against vaccine strains. Two-year fold changes in titers were estimated using multivariable power-law models adjusted for age and baseline titer. We analyzed 173 sera from 57 HIVE participants and 259 sera from 60 EPI-HK participants. Initial HAI geometric mean titers ranged from 12.3-123.4 in HIVE and 6.3-40.9 in EPI-HK. Among those with >1:40 baseline titers in HIVE, fold-change estimates indicated waning for H1N1 strains, including A/Brisbane (0.70 [95% CI: 0.56,0.86]), A/Idaho (0.40 [0.32,0.50]), and A/Michigan (0.43 [0.34,0.52]), while H3N2 and influenza B showed minimal or no waning. In EPI-HK, fold-change estimates demonstrated heterogeneous patterns by strain for H1N1, and waning for selected H3N2 strains, including A/Cambodia (0.44 [0.29,0.65]) and A/Singapore (0.48 [0.33,0.69]). MN results were consistent with HAI findings. Influenza antibody responses during the pandemic showed heterogeneous, strain-specific changes rather than uniform decline. These findings suggest that population immunity was maintained for many strains despite reduced viral circulation, with waning occurring in particular strains and varying by population.

PMID 43043347
阅读全文 →
PubMedGeriatrie et psychologie neuropsychiatrie du vieillissement2026-11-17

[Specific considerations regarding vaccine administration in older people].

Berrut Gilles G, Colliat François F, Blain Hubert H

In France, seasonal influenza was responsible for approximately 29,000 hospitalisations during the 2024-2025 season. An estimated 17,000 excess all-cause deaths were recorded during the same season, 90% of them among people aged 65 years and over. The 2026 immunisation schedule now recommends five to six vaccinations for this age group, yet influenza vaccination coverage among people aged 65 and over remains at 54%, and at 21% among nursing home staff. This review examines the implementation of vaccination programmes in long-term care facilities and home settings, including barriers and enablers, necessary precautions, and the role of informal caregivers. In long-term care facilities, effective implementation relies on a multimodal organisational intervention whose components have a cumulative effect: committed leadership, a designated vaccination coordinator, free vaccination on site, vaccine-specific information, and engaging communication materials. In home settings, it depends on proactively offering vaccination, expanding healthcare professionals' scope of practice for vaccination, and coordinating vaccinations. Precautions concern injections in patients receiving anticoagulant therapy, consent for adults under legal protection, and continued adherence to infection prevention measures. Informal caregivers remain an underused resource.

PMID 43042681
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多trivalent influenza vaccine